A KHN analysis found that 47 of the drugs cost Medicare and Medicaid almost $12 billion in 2016. The spending totals don’t include rebates, which drugmakers return to the government after paying for the drugs upfront but are not public.
The U.S. Food and Drug Administration has approved a revised label for cancer drug Gleevec following a clinical study that showed better results with prolonged use of the drug compared with the 12 months that has been recommended. The U.S. regulator also granted regular approval of Gleevec. Marketed by Swiss pharmaceutical company Novartis Pharmaceuticals (NYSE:NVS) […]
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.